The estimated Net Worth of Angelos M. Stergiou is at least $1.7 Milione dollars as of 5 December 2022. Angelos Stergiou owns over 6,494 units of SELLAS Life Sciences Inc stock worth over $213,429 and over the last 7 years he sold SLS stock worth over $59,296. In addition, he makes $1,426,610 as President, Chief Executive Officer e Director at SELLAS Life Sciences Inc.
Sign up
Angelos Stergiou SLS stock SEC Form 4 insiders trading
Angelos has made over 3 trades of the SELLAS Life Sciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 6,494 units of SLS stock worth $16,949 on 5 December 2022.
The largest trade he's ever made was selling 23,277 units of SELLAS Life Sciences Inc stock on 31 December 2018 worth over $29,096. On average, Angelos trades about 2,658 units every 120 days since 2017. As of 5 December 2022 he still owns at least 161,689 units of SELLAS Life Sciences Inc stock.
You can see the complete history of Angelos Stergiou stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Angelos Stergiou biography
Dr. Angelos M. Stergiou M.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Stergiou founded our predecessor entity that completed a business combination with Galena Biopharma on December 29, 2017, or Private SELLAS, in 2012 and served as the President and Chief Executive Officer and a director since that time, both as Chairman from 2012 to July 2016, and as Vice Chairman from July 2016 to December 2017. In connection therewith, Dr. Stergiou led the negotiation of an exclusive license agreement with Memorial Sloan Kettering Cancer Center, or MSK, to develop and commercialize MSK’s WT1 peptide vaccine technology, which was satisfied in part by the transfer to MSK of certain of Dr. Stergiou’s shares in Private SELLAS. Dr. Stergiou also co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company where he served as President and Chief Operating Officer from 2009 to 2011. From 2004 to 2008 Dr. Stergiou served as Vice President and Head of Drug Development at Accentia Biopharmaceuticals, Inc and also served in the same capacity as well as Chief Medical Officer at its subsidiary Biovest International, Inc. during the same time. While at Biovest International, Inc., Dr. Stergiou led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, which was presented at the American Society of Clinical Oncology plenary session in 2009. Dr. Stergiou started his biotechnology career in 2002 at PAION AG where he served as its U.S. program lead of desmoteplase (DEDAS) and served on the joint steering and oversight committee of PAION AG with Forest Laboratories, Inc. in 2003-2004. Dr. Stergiou holds an M.D. from the U.S. American Institute of Medicine and a Sc.D. h.c. from Kentucky Wesleyan College and received his undergraduate degree in pre-medicine, biology and chemistry from Kentucky Wesleyan College.
What is the salary of Angelos Stergiou?
As the President, Chief Executive Officer e Director of SELLAS Life Sciences Inc, the total compensation of Angelos Stergiou at SELLAS Life Sciences Inc is $1,426,610. There are no executives at SELLAS Life Sciences Inc getting paid more.
How old is Angelos Stergiou?
Angelos Stergiou is 44, he's been the President, Chief Executive Officer e Director of SELLAS Life Sciences Inc since 2017. There are 12 older and 3 younger executives at SELLAS Life Sciences Inc. The oldest executive at SELLAS Life Sciences Group Inc is David Scheinberg, 64, who is the Director.
What's Angelos Stergiou's mailing address?
Angelos's mailing address filed with the SEC is C/O SELLAS LIFE SCIENCES GROUP, INC.,, 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036.
Insiders trading at SELLAS Life Sciences Inc
Over the last 7 years, insiders at SELLAS Life Sciences Inc have traded over $74,616 worth of SELLAS Life Sciences Inc stock. The most active insiders traders include John Varian, Jane Wasman e David A Scheinberg. On average, SELLAS Life Sciences Inc executives and independent directors trade stock every 205 days with the average trade being worth of $6,842. The most recent stock trade was executed by Angelos M. Stergiou on 5 December 2022, trading 6,494 units of SLS stock currently worth $16,949.
What does SELLAS Life Sciences Inc do?
σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.
What does SELLAS Life Sciences Inc's logo look like?
Complete history of Angelos Stergiou stock trades at SELLAS Life Sciences Inc
SELLAS Life Sciences Inc executives and stock owners
SELLAS Life Sciences Inc executives and other stock owners filed with the SEC include:
-
Angelos Stergiou,
President, Chief Executive Officer, Director -
Dr. Angelos M. Stergiou M.D., ScD h.c.,
Founder, Pres, CEO & Director -
Barbara Wood,
Executive Vice President, General Counsel, Corporate Secretary -
Barbara A. Wood,
Exec. VP, Gen. Counsel & Sec. -
Dr. Dragan Cicic M.D., MBA,
Sr. VP of Clinical Devel. -
John Burns,
Interim Principal Accounting Officer, Vice President - Finance, Corporate Controller -
Dr. Dragan Cicic,
Sr. VP of Clinical Devel. -
Jane Wasman,
Independent Chairman of the Board -
John Varian,
Independent Director -
Robert Van Nostrand,
Independent Director -
David Scheinberg,
Director -
Dragan Cicic,
Senior Vice President - Clinical Development -
Jörg W. Breitkopf,
Head of Clinical Operations -
Robert M. Francomano,
Sr. VP & Chief Commercial Officer -
John Thomas Burns CPA,
Sr. VP of Fin. & Chief Accounting Officer -
David D. Moser,
VP of Legal Affairs -
Jörg W. Breitkopf,
Head of Clinical Operations -
Dr. Christopher R. Shackleton,
Director of Clinical and Bus. Operations -
Martin G. Baum,
Chief Operating Officer -
John Thomas Burns CPA, CPA,
VP of Fin., Corp. Controller & Chief Accounting Officer -
Fabio Lopez,
Director -
Nicholas J. Sarlis,
Chief Medical Officer and SVP -
Robert Francomano,
Chief Commercial Officer -
Fabio Eqc Private Markets S...,
-
Stephen F Ghiglieri,
Director -
Gregory M Torre,
CRO and SVP -
Fabio Eqc Private Markets S...,
-
Gene Mack,
CFO and Treasurer -
Katherine Bach Kalin,
Director